Clinical Trial Update: Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Branebrutinib in active autoimmune diseases (systemic lupus erythematosus, primary Sjögren's syndrome) and rheumatoid arthritis, with an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• Abatacept (abatacept)
• branebrutinib (branebrutinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Autoimmune Disorder, Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2024-01-16